Sanofi SA
SAN: XPAR (FRA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
€824.00 | Knkh | Xhfgkwmr |
Sanofi’s Acquisition of Provention Bio Adds a New Diabetes Drug at a Reasonable Price
Sanofi’s announced acquisition of Provention Bio adds new diabetes drug Tzield to Sanofi’s entrenched cardiometabolic platform. However, we don’t see the nearly $3 billion deal as significantly affecting Sanofi's fair value estimate or wide moat.